awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8
Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
P2860
Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dbda43dcebf844f68f95d3b6a24a5e77ecac02a4
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer